← Back to Screener
Lantern Pharma Inc. Common Stock (LTRN)
Price$2.54
Favorite Metrics
Price vs S&P 500 (26W)-51.26%
Price vs S&P 500 (4W)-0.15%
Market Capitalization$27.24M
All Metrics
Book Value / Share (Quarterly)$0.87
P/TBV (Annual)0.78x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.53
Price vs S&P 500 (YTD)-22.77%
EPS (TTM)$-1.75
10-Day Avg Trading Volume0.50M
EPS Excl Extra (TTM)$-1.75
EPS (Annual)$-1.93
ROI (Annual)-98.08%
Cash / Share (Quarterly)$1.12
ROA (Last FY)-81.27%
EBITD / Share (TTM)$-1.80
ROE (5Y Avg)-41.96%
Cash Flow / Share (Annual)$-1.65
P/B Ratio2.84x
P/B Ratio (Quarterly)5.01x
Net Income / Employee (Annual)$-1
ROA (TTM)-97.38%
EPS Incl Extra (Annual)$-1.93
Current Ratio (Annual)5.83x
Quick Ratio (Quarterly)3.06x
3-Month Avg Trading Volume0.39M
52-Week Price Return-31.44%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$4.18
52-Week High$5.74
EPS Excl Extra (Annual)$-1.93
CapEx CAGR (5Y)4.73%
26-Week Price Return-47.28%
Quick Ratio (Annual)5.54x
13-Week Price Return-27.98%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.33x
Enterprise Value$18.847
Revenue / Employee (Annual)$0
Cash / Share (Annual)$2.23
3-Month Return Std Dev124.74%
Net Income / Employee (TTM)$-1
ROE (Last FY)-98.08%
EPS Basic Excl Extra (Annual)$-1.93
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.75
ROI (TTM)-125.98%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$5.16
Price vs S&P 500 (52W)-61.27%
Year-to-Date Return-20.13%
5-Day Price Return29.41%
EPS Normalized (Annual)$-1.93
ROA (5Y Avg)-37.56%
Month-to-Date Return76.64%
Cash Flow / Share (TTM)$-1.39
EBITD / Share (Annual)$-2.00
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-41.93%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.75
P/TBV (Quarterly)0.97x
P/B Ratio (Annual)1.62x
Book Value / Share (Annual)$1.96
Price vs S&P 500 (13W)-28.66%
Beta2.21x
Revenue / Share (TTM)$0.00
ROE (TTM)-125.98%
52-Week Low$1.11
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
LTRNLantern Pharma Inc. Common Stock | — | — | — | — | $2.54 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Lantern Pharma uses artificial intelligence to accelerate oncology drug discovery and development. The company's proprietary RADR platform applies machine learning to oncology-focused data, reducing drug development costs and timelines. Its growing pipeline of precision cancer therapies is powered by AI-driven insights and partnerships with leading scientific experts.